RxLightning Taps Patient Advocate and NAMAPA Co-Founder Elizabeth Johnson as Director of Product Management

New Albany, Indiana--(Newsfile Corp. - April 20, 2021) - RxLightning, a healthcare technology company that simplifies and automates the complex specialty medication enrollment process through a single comprehensive, user-friendly platform, today announced the addition of Elizabeth Johnson for the new role of Director of Product Management. Johnson is a Licensed Practical Nurse (LPN) and co-founder of the National Association of Medication Access & Patient Advocacy (NAMAPA), a non-profit that focuses on empowering healthcare advocates by providing a collaborative community focused on resources to navigate medication access and support.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • RxLightning hires new Director of Product Management, Elizabeth Johnson.
  • Johnson brings front-line experience in specialty medication access and is a passionate patient advocate.
  • New hire comes on the heels of RxLightning's recent announcement that it would make its technology available to providers at no cost.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7294/81010_figure1_550.jpg

Click image above to view full announcement.

About RxLightning

Founded in New Albany, Indiana in 2020, RxLightning digitizes, automates and streamlines the historically complicated manual enrollment process of starting a patient on specialty medications. Specialty medications are expected to account for 70% of new medication launches through 2023. With RxLightning, healthcare providers can quickly and easily complete the enrollment process for every specialty medication in every therapeutic area, helping reduce paperwork, streamline communication, and accelerate the speed of therapy for patients. Learn more at rxlightning.com.

Contacts:
Kriste Goad
(615)440-9049
kg@growwithfuoco.com

Source: RxLightning

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/81010

Back to news